Clinical trial
Monoclonal Antibody for Treatment of Inhalation Anthrax
NCT00138411 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00138411 |
|---|---|
| Title | Monoclonal Antibody for Treatment of Inhalation Anthrax |
| Official title | Randomized, Placebo-Controlled, Double Blind, Dose-Escalation Phase I Study of the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 [Anthim(TM)] and Its Potential Interaction With Ciprofloxacin |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bacillus Anthracis (Anthrax) |
| Intervention type | Drug |
| Interventions | Ciprofloxacin 500 mg, ETI-204 (Anthim) |
| Enrollment | 36 |
| Start date | Oct 1, 2005 |
| Completion | Mar 1, 2006 |
| First posted | Aug 30, 2005 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: